New study finds that blood test could increase the impact of lung cancer screening with low-dose computed tomography

Screening by low-dose computed tomography (LDCT) can reduce lung cancer mortality among high-risk individuals with a smoking history. However, many lung cancers occur among individuals with a history of smoking who are not eligible for screening, and this limits the impact of screening. A new study from the International Agency for Research on Cancer (IARC) and partners from the Lung Cancer Cohort Consortium (LC3) suggests that a blood-based test could improve the selection of individuals who should be offered LDCT lung cancer screening. The study is published today in the Journal of the American Medical Association.

Zahed H, Feng X, Alcala K, Smith-Byrne K, Moez E, Guida F, et al.
Biomarker-based eligibility for lung cancer screening: validation of the protein-based INTEGRAL-Risk model
JAMA. Published online 18 May 2026;
https://doi.org/10.1001/jama.2026.8044

Read IARC Press Release 380

Read the article